Select Neurocognitive Impairment in HIV-infected Women: Associations with HIV Viral Load, Hepatitis C Virus, and Depression, but Not Leukocyte Telomere Length
Overview
Authors
Affiliations
Background: Through implementation of combination antiretroviral therapy (cART) remarkable gains have been achieved in the management of HIV infection; nonetheless, the neurocognitive consequences of infection remain a pivotal concern in the cART era. Research has often employed norm-referenced neuropsychological scores, derived from healthy populations (excluding many seronegative individuals at high risk for HIV infection), to characterize impairments in predominately male HIV-infected populations.
Methods: Using matched-group methodology, we assessed 81 HIV-seropositive (HIV+) women with established neuropsychological measures validated for detection of HIV-related impairments, as well as additional detailed tests of executive function and decision-making from the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Results: On validated tests, the HIV+ women exhibited impairments that were limited to significantly slower information processing speed when compared with 45 HIV-seronegative (HIV-) women with very similar demographic backgrounds and illness comorbidities. Additionally, select executive impairments in shifting attention (i.e., reversal learning) and in decision-making quality were revealed in HIV+ participants. Modifiers of neurocognition in HIV-infected women included detectable HIV plasma viral load, active hepatitis C virus co-infection, and self-reported depression symptoms. In contrast, leukocyte telomere length (LTL), a marker of cellular aging, did not significantly differ between HIV+ and HIV- women, nor was LTL associated with overall neurocognition in the HIV+ group.
Conclusions: The findings suggest that well-managed HIV infection may entail a more circumscribed neurocognitive deficit pattern than that reported in many norm-referenced studies, and that common comorbidities make a secondary contribution to HIV-related neurocognitive impairments.
Biosafety and mental health: Virus induced cognitive decline.
Du C, Li G, Han G Biosaf Health. 2025; 5(3):159-167.
PMID: 40078510 PMC: 11895046. DOI: 10.1016/j.bsheal.2023.04.002.
Yang N, Hsieh A, Chen Z, Campbell A, Gadawska I, Kakkar F Viruses. 2024; 16(5).
PMID: 38793637 PMC: 11125719. DOI: 10.3390/v16050755.
Sassoon S, Le Berre A, Fama R, Asok P, Hardcastle C, Chu W J HIV AIDS Infect Dis. 2024; 4(1).
PMID: 38481564 PMC: 10936226. DOI: 10.17303/jaid.2017.3.101.
Sassoon S, Fama R, Pohl K, Pfefferbaum A, Sullivan E Neurobiol Stress. 2024; 29:100608.
PMID: 38323165 PMC: 10844640. DOI: 10.1016/j.ynstr.2024.100608.
Qin P, He J, Yang X, Chen S, Chen X, Jiang H JMIR Public Health Surveill. 2022; 8(8):e32968.
PMID: 35984684 PMC: 9440416. DOI: 10.2196/32968.